Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical ...

Zai Lab announces $200M share offering amid 47% revenue growth and plans for KarXT submission in China. Multiple companies report changes: Kronos Bio seeks alternatives, Allogene halts trial ...

Among the Fed speakers on the road today is Federal Reserve Chair Jerome Powell, who will be participating on a panel hosted by the Dallas Regional Chamber, the World Affairs Council of DFW and the ...

Asian equities traded in the US as American depositary receipts were higher Thursday morning, rising 0.6% to 2,033.68 on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by diagnostic ...

Before joining Mirati, Dr. Sandler was the President, Global Head of Development in Oncology at Zai Lab. Prior to that, he ...

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 46%. Looking ahead, ...

Limited announced that it has commenced an underwritten public offering of $200M of American depositary shares, ADSs, each ...

Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...

Zai Lab Ltd (HK:9688) has released an update. Zai Lab Limited has announced a proposed follow-on underwritten public offering of $200 million ...

Zai Lab Ltd (HK:9688) has released an update. Zai Lab Limited has updated its risk factors in a new Form 8-K filing with the U.S. Securities ...

Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development ...

at 16:15 Zai Lab Announces Proposed Public Offering of American Depositary Shares Zai Lab Limited ("Zai Lab" or the "Company") , an innovative, commercial-stage biopharmaceutical company, today ...